Trevi Therapeutics, Inc. Operating Lease, Payments
Trevi Therapeutics, Inc. (TRVI) reported Operating Lease, Payments of $351.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:OperatingLeasePayments · last filed 2026-03-17
- Trevi Therapeutics, Inc. operating lease, payments for the quarter ending 2025-12-31 was $91.00K, a 15.19% increase year-over-year.
- Trevi Therapeutics, Inc. operating lease, payments for the quarter ending 2025-09-30 was $91.00K, a 16.67% increase year-over-year.
- Trevi Therapeutics, Inc. operating lease, payments for the quarter ending 2025-06-30 was $91.00K, a 31.88% increase year-over-year.
- Trevi Therapeutics, Inc. operating lease, payments for the quarter ending 2025-03-31 was $78.00K, a 13.04% increase year-over-year.
- Trevi Therapeutics, Inc. operating lease, payments for fiscal 2025 was $351.00K, a 15.84% increase from fiscal 2024.
- Trevi Therapeutics, Inc. operating lease, payments for fiscal 2024 was $303.00K, a 31.17% increase from fiscal 2023.
- Trevi Therapeutics, Inc. operating lease, payments for fiscal 2023 was $231.00K, a 77.69% increase from fiscal 2022.
- Trevi Therapeutics, Inc. operating lease, payments for fiscal 2022 was $130.00K, a 6.47% decline from fiscal 2021.
| Period end | Operating Lease, Payments 3 month | Operating Lease, Payments 3 month as first filed | Operating Lease, Payments 6 month | Operating Lease, Payments 9 month | Operating Lease, Payments 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $182.00K derived: sum of 2 quarters · filed 2026-03-17 | $273.00K derived: sum of 3 quarters · filed 2026-03-17 | $351.00K 10-K · filed 2026-03-17 | |
| 2025-09-30 | $91.00K 10-Q · filed 2025-11-13 | $182.00K derived: sum of 2 quarters · filed 2025-11-13 | $260.00K 10-Q · filed 2025-11-13 | $339.00K derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-06-30 | $91.00K 10-Q · filed 2025-08-07 | $169.00K 10-Q · filed 2025-08-07 | $248.00K derived: sum of 3 quarters · filed 2026-03-17 | $326.00K derived: sum of 4 quarters · filed 2026-03-17 | |
| 2025-03-31 | $78.00K 10-Q · filed 2025-05-08 | $157.00K derived: sum of 2 quarters · filed 2026-03-17 | $235.00K derived: sum of 3 quarters · filed 2026-03-17 | $304.00K derived: sum of 4 quarters · filed 2026-03-17 | |
| 2024-12-31 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $157.00K derived: sum of 2 quarters · filed 2026-03-17 | $226.00K derived: sum of 3 quarters · filed 2026-03-17 | $303.00K 10-K · filed 2026-03-17 | |
| 2024-09-30 | $78.00K 10-Q · filed 2025-11-13 | $147.00K derived: sum of 2 quarters · filed 2025-11-13 | $224.00K 10-Q · filed 2025-11-13 | $285.00K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | $69.00K 10-Q · filed 2025-08-07 | $138.00K 10-Q · filed 2025-08-07 | $207.00K derived: sum of 3 quarters · filed 2025-08-07 | $276.00K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $69.00K 10-Q · filed 2025-05-08 | $138.00K derived: sum of 2 quarters · filed 2025-05-08 | $207.00K derived: sum of 3 quarters · filed 2025-05-08 | $276.00K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $138.00K derived: sum of 2 quarters · filed 2025-03-18 | $207.00K derived: sum of 3 quarters · filed 2025-03-18 | $231.00K 10-K · filed 2025-03-18 | |
| 2023-09-30 | $69.00K 10-Q · filed 2024-11-06 | $138.00K derived: sum of 2 quarters · filed 2024-11-06 | $162.00K 10-Q · filed 2024-11-06 | $197.00K derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $69.00K 10-Q · filed 2024-08-08 | $93.00K 10-Q · filed 2024-08-08 | $128.00K derived: sum of 3 quarters · filed 2024-08-08 | $164.00K derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $24.00K 10-Q · filed 2024-05-07 | $59.00K derived: sum of 2 quarters · filed 2024-05-07 | $95.00K derived: sum of 3 quarters · filed 2024-05-07 | $119.00K derived: sum of 4 quarters · filed 2024-05-07 | |
| 2022-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | $71.00K derived: sum of 2 quarters · filed 2024-03-20 | $95.00K derived: sum of 3 quarters · filed 2024-03-20 | $130.00K 10-K · filed 2024-03-20 | |
| 2022-09-30 | $36.00K 10-Q · filed 2023-11-09 | $60.00K derived: sum of 2 quarters · filed 2023-11-09 | $95.00K 10-Q · filed 2023-11-09 | $130.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $24.00K 10-Q · filed 2023-08-10 | $59.00K 10-Q · filed 2023-08-10 | $94.00K derived: sum of 3 quarters · filed 2023-08-10 | $129.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $35.00K 10-Q · filed 2023-05-11 | $70.00K derived: sum of 2 quarters · filed 2023-05-11 | $105.00K derived: sum of 3 quarters · filed 2023-05-11 | $140.00K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $70.00K derived: sum of 2 quarters · filed 2023-03-16 | $105.00K derived: sum of 3 quarters · filed 2023-03-16 | $139.00K 10-K · filed 2023-03-16 | |
| 2021-09-30 | $35.00K 10-Q · filed 2022-11-10 | $70.00K derived: sum of 2 quarters · filed 2022-11-10 | $104.00K 10-Q · filed 2022-11-10 | $139.00K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $35.00K 10-Q · filed 2022-08-11 | $69.00K 10-Q · filed 2022-08-11 | $104.00K derived: sum of 3 quarters · filed 2022-08-11 | $127.00K derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $34.00K 10-Q · filed 2022-05-12 | $69.00K derived: sum of 2 quarters · filed 2022-05-12 | $92.00K derived: sum of 3 quarters · filed 2022-05-12 | $127.00K derived: sum of 4 quarters · filed 2022-05-12 | |
| 2020-12-31 | $35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $58.00K derived: sum of 2 quarters · filed 2022-03-17 | $93.00K derived: sum of 3 quarters · filed 2022-03-17 | $138.00K 10-K · filed 2022-03-17 | |
| 2020-09-30 | $23.00K 10-Q · filed 2021-11-10 | $58.00K derived: sum of 2 quarters · filed 2021-11-10 | $103.00K 10-Q · filed 2021-11-10 | $137.00K derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $35.00K 10-Q · filed 2021-08-12 | $80.00K 10-Q · filed 2021-08-12 | $114.00K derived: sum of 3 quarters · filed 2021-08-12 | $148.00K derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $45.00K 10-Q · filed 2021-05-13 | $79.00K derived: sum of 2 quarters · filed 2021-05-13 | $113.00K derived: sum of 3 quarters · filed 2021-05-13 | $136.00K derived: sum of 4 quarters · filed 2021-05-13 | |
| 2019-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $68.00K derived: sum of 2 quarters · filed 2021-03-25 | $91.00K derived: sum of 3 quarters · filed 2021-03-25 | $125.00K 10-K · filed 2021-03-25 | |
| 2019-09-30 | $34.00K 10-Q · filed 2020-11-12 | $57.00K derived: sum of 2 quarters · filed 2020-11-12 | $91.00K 10-Q · filed 2020-11-12 | $114.00K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | $23.00K 10-Q · filed 2020-08-13 | $57.00K 10-Q · filed 2020-08-13 | $80.00K derived: sum of 3 quarters · filed 2020-08-13 | $119.00K derived: sum of 4 quarters · filed 2020-08-13 | |
| 2019-03-31 | $35.00K 10-Q · filed 2020-05-07 | $34.00K 10-Q · filed 2019-06-14 | $57.00K derived: sum of 2 quarters · filed 2020-05-07 | $96.00K derived: sum of 3 quarters · filed 2020-05-07 | $126.00K derived: sum of 4 quarters · filed 2020-05-07 |
| 2018-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $61.00K derived: sum of 2 quarters · filed 2020-03-16 | $91.00K derived: sum of 3 quarters · filed 2020-03-16 | $117.00K 10-K · filed 2020-03-16 | |
| 2018-09-30 | $39.00K 10-Q · filed 2019-11-14 | $69.00K derived: sum of 2 quarters · filed 2019-11-14 | $95.00K 10-Q · filed 2019-11-14 | ||
| 2018-06-30 | $30.00K 10-Q · filed 2019-08-12 | $56.00K 10-Q · filed 2019-08-12 | |||
| 2018-03-31 | $26.00K 10-Q · filed 2019-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |